Tislelizumab for relapsed/refractory classical Hodgkin lymphoma: 3-year follow-up and correlative biomarker analysis.

Yuqin SongQuanli GaoHuilai ZhangLei FanJian-Feng ZhouDehui ZouWei LiHaiyan YangTing LiuQuanshun WangFangfang LvHaiyi GuoXia ZhaoDan WangPei ZhangYidi WangLei WangTengfei LiuYun ZhangZhirong ShenJane HuangJun Zhu

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

With extended follow-up, tislelizumab yielded long-term benefits and demonstrated a favorable safety profile for patients with relapsed/refractory cHL. This trial was registered at clinicaltrials.gov as NCT03209973.

Keyphrases

hodgkin lymphoma
clinical trial
study protocol
phase iii
acute lymphoblastic leukemia
phase ii
open label
electron microscopy